Transcript No Slide Title
Rudy Dekeyser 21/04/05
•
origin of the species
•
mission & objectives
•
creating an innovative environment
•
is basic high quality research compatible with tech transfer?
•
origin of the species
•
mission & objectives
•
creating an innovative environment
•
is basic high quality research compatible with tech transfer?
Origin of the species
Antwerp Ghent Brussels Louvain Diepenbeek
Origin of the species
Step 1. Flemish government evaluates the life sciences research [1994]
Origin of the species
The 1994 conclusions:
big names in science
but lack of structural support critical mass translation in industrial activities
Origin of the species
The conventional approach:
Dedicate a certain volume of an existing granting body to life sciences research
danger:
slice it thin
lack of sustainability
Establish a novel independent research institution
danger:
disturb the equilibrium
lag phase
Origin of the species
Step 2. The VIB concept
unite existing quality
build synergy and critical mass
research
tech transfer
Origin of the species
VIB – unite existing quality 60 biotech teams in 5 universities evaluation select 9 excellent teams
U2
Origin of the species
U1 U3 VIB vzw U4 U5
Origin of the species
VIB – create critical mass
Flemish government invests
5y x 25M € = 125.000.000 € = doubling research budget overnight = creating critical mass
Framework agreement:
•
long term commitment
•
in depth evaluation every 5 year
Origin of the species
VIB – create synergy
Framework agreement with universities
key output: scientific publications www.nature.com/reviews/genetics 752 / October 2004 / volume 5
Origin of the species
VIB – create synergy
Framework agreement with universities
tech transfer:
•
IPR
– – –
joint ownership management: VIB costs: VIB
•
marketing/exploitation: VIB
Origin of the species
VIB – create synergy
Framework agreement with universities
tech transfer - return € € € patent cost inventors VIB 10 50 univ 40 40 Department 50 VIB 10
Origin of the species
VIB – create synergy
Framework agreement with universities
tech transfer – return UNIV : VIB : 10 + 40 + 40 = 90% 10 + 40 + 40 = 90%
Origin of the species
VIB – key facts & figures
foundation
legal entity
field
budget 2004
headcount : : : : : 1996 not-for-profit life sciences ~ 60 mio € ~ 850
•
origin of the species
•
mission & objectives
•
creating an innovative environment
•
is basic high quality research compatible with tech transfer?
Mission
Molecular sciences to improve the quality of life
Objectives
conduct frontline basic research
translate inventions into products for the benefit of society
inform the public
•
origin of the species
•
mission & objectives
•
creating an innovative environment
•
is basic high quality research compatible with tech transfer?
VIB - Research
Major fields:
Oncology
Cardiovascular/angiogenesis
Neurobiology
Inflammation/immunology
Developmental biology
Plant system biology
Microbiology
VIB - Research
membrane
FADD casp8 TNF TNF-R55 TNF-R75 TRADD Ub TRAF2 RIP Ub MAP3K Ub IKK
IKK
/
P IKK
/
P
apoptosis
A20 ABIN P I
B p50 p65 P Ub I
B P P p50 p65
inflammation
NF-
B dependent genes p50 p65
nucleus
VIB - Research Novel treatment for IBD in clinical trial
Colitis ulcerosa Recombinant L.lactis, expressing IL-10 Crohn’s disease healthy colon
VEGF
d/d
mice show adult onset ALS phenotype
VIB - Research C/ A -2578 CTG1 (-540) G/ A -1154 G/ C -634G/C ATG (1) 1 2 3 4 5 6 7 8 L-VEGF Cleavage gDNA mRNA Protein
Reduced levels of VEGF increase the risk for ALS
VIB - Research Quantitative N-teromics
N N
Arg Arc
16 O
C
16 O
H
18 O
C
18 O
H
Ex.: Heatmap of ratios of amino-terminal peptides for 700 IDs from T-Lymphocyte According to reverse phase chromatography position According to ratio (O18/O16)
x
VIB - Research
VIB – Tech Transfer
Tech Transfer = = Technology Transfer Knowledge Transfer = the movement of knowledge between different parties = the transfer of knowledge from an academic institution to industry = patenting, licensing and establishing start-ups = mining of knowledge => optimize knowledge creation
VIB - Research
Target :
frontline Create the environment:
recognise excellence
top performance => budget low performance => budget
excellence bonus
recruit internationally
VIB – Research international recognition 39 nationalities 58% 23 % 11% 6,5 % 1% European countries Asia N&S America Africa Australia % internationalisation
30 20 10 0 1997 1999 2001 2003
VIB - Research
Target :
frontline Create the environment:
recognise excellence
up to date infrastructure
UGent-VIB research building
VIB - Research
Target :
frontline Create the environment:
recognise excellence
up to date infrastructure
access to advanced technology platforms
VIB microarray facility
VIB proteomics core facility (Source: PhD thesis Kris Gevaert, 2000)
VIB Genetic Service Facility
sequencing
STR-genotyping
SNP discovery
SNP analysis
VIB technology – model organisms yeast drosophila xenopus zebrafish mouse arabidopsis
VIB technologies Bio-informatics
VIB - Research
Target :
frontline Create the environment:
Stimulate debate and interaction
GLC
VIB seminar
VIB newsletter
science clubs
PhD program
VIB - Research
Quality assurance:
•
IAB
Institutional Advisory Board 2004
VIB - Research
Quality assurance IAB SAB
strategic plan organigram [critical density]
VIB - Research
VIB - Research
Quality assurance
IAB SAB
strategic plan organigram
performance criteria
VIB - Research
Performance criteria:
scientifically ≥ 45 publications in IF > 10 journals ≥ 125 publications in IF > 5 journals
tech transfer ≥ 25 patent applications 50% granted ≥ 5 mio € industry funding
education ≥ 35 PhD’s
VIB - Research 60 40 20 0 200 180 160 140 120 100 80 69 1995
IF > 5
187 2004
X 2.7
IF > 10
60 50 40 30 20 10 0 16 1995 53 2004
X 3.3
VIB – Tech Transfer research records of invention IPR agreements existing companies start-ups • facilitate the commercialisation of research results for the benefit of society • promote economic growth • job creation • generate research € to dept.
VIB – Tech Transfer
Disclosure and recording of inventions Policy:
adapt to academic environment
pro-active
minimize administrative hurdles
treat with priority
# ROI 60 50 40 30 20 10 0 96
VIB - Tech Transfer Inventions
97 98 99 2000 2001 2002 2003 2004
VIB - Tech Transfer ROI-benchmark 3 2,5 2 1,5 1 0,5 0 V IB Can. Inst.
US Inst.
Cal Tech US Univ.
ARCH Stanford
# P A
VIB - Tech Transfer # patent applications
3 5 3 0 2 5 2 0 15 10 5 0 9 5 9 6 9 7 9 8 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4
VIB - Tech Transfer
Patent applications (PA)
VIB Benchmark : :
~
48% ROI => PA
~
50% ROI => PA
EU Priority filing US UK 2 nd filing VIB – Tech Transfer portfolio management PCT filing National phase Granting Search report Written opinion Preliminary Examination Report
VIB – Tech Transfer Budgets/year - cumulative
35000 30000 25000 20000 15000 10000 5000 0 '96 '97 '98 '99 '00 '01 '02 '03 '04
VIB - Tech Transfer
Licensing/R&D: some collaborators
Pfizer
Novartis
Johnson & Johnson
Solvay
Abbott
Bayer
Innogenetics
Tibotec
Galapagos
CropDesign
Ablynx
Tigenix
VIB - Tech Transfer
Start-up: basic principles VIB operates in a very hands-on manner by playing the role of seed financier:
conceptualize and write business plan
strengthen the technology/product base via inlicensing assist in bringing the team in place
road show to raise venture money assist in the due diligence process
VIB - Tech Transfer
Start-up: case study - nanobody
Broad application spectrum
•
diagnostics/proteomics
•
therapeutics
•
immuno-affinity
•
feed/food
VIB - Tech Transfer
Start-up: case study – nanobody (1) Technology building
secured access to 3 basic patents covering product claims and production methodology (VUB)
filed 6 more patent families
> 40 patent applications and patents (2) Strategic investments:
VIB grant complemented with:
•
tech transfer project
•
IWT grant
VIB - Tech Transfer
Start-up: case study – nanobody (3) Business plan (Ablynx) (4) Attract lead investor (GIMV) (5) Establish legal entity (VIB + GIMV) (6) Attract CEO (M. Vaeck, ex-COO Ceres) (7) Ad interim management
•
recruit first employees
•
rent lab space
• •
furnish labs establish contacts with potential licensees
Ablynx nv
Biopharma Foundation Location CEO Venture Capital 1st round
Investors
Venture Capital 2nd round : New investors : : : : : :
Employees : 2001 Ghent Dr. Mark Vaeck 5 M € GIMV, BFV, Sofinnova, Gilde 25 M € Abingworth, Alta Partners 40
Devgen nv
Biopharma & agbio
Foundation
Location
CEO
Venture Capital 1st round
Investors 1st round
Venture Capital 2 nd round
New investors
Employees : : : : : 1997 Ghent Dr. Thierry Bogaert 9.4 M € GIMV, Abingworth, BVF : 29 M € : Advent, LSP, Rendex, ING, DV, KBC, M&M : 95
CropDesign nv
Agbio Foundation Location CEO: Venture Capital 1st round Investors 1st round : : : : :
Venture Capital 2 nd New Investors round : :
Venture Capital 3th round
Employees : : 1998 Ghent Dr. Johan Cardoen 11 M USD GIMV, Atlas Venture, Sofinnova, BFF 25.6 M € Gilde, ING, DV, Burrill Agbio, KBC, Technolife 2010 16 M € 70
Peakadilly nv
Biopharma
Foundation
Location
CEO
Capital 1st round
Income
Employees : : : : : : 2004 Ghent Koen Kas VIB 3 mio € 10
Tech Transfer - 2004 Start-ups: employees
200 180 160 140 120 100 80 60 40 20 0 '97 '98 '99 '00 '01 '02 '03 '04 Totaal
VIB start-up
Benefit for society:
multiple therapeutics under development novel agronomically improved crop varieties under deveopment
VIB - Tech Transfer
Ghent Technology Park DeVGen research facilities University of Ghent/VIB Innogenetics VIB Bio incubator 2 Bayer Bio Science VIB Bio incubator 1 Innovation& Incubation centre 2 (University of Ghent) Innovation & Incubation centre 1 (University of Gent) Crop Design Service Center for biotech Buildings planned or under construction
Conclusion
scientific output and quality improved significantly
tech transfer output has increased from almost zero to significant
•
origin of the species
•
mission & objectives
•
creating an innovative environment
•
is basic high quality research compatible with tech transfer?
Balancing science & Tech Transfer
Groups with collaboration Groups without collaboration
science technology basic applied
Source: K. Debackere et al., in prep.
Balancing science & Tech Transfer
Table 1a – average number of SCIE publications (1998-2000) Inventors Non-inventors Complete sample 35,8 11,7 Sample without outliers (# pubs < 90) 22,8 12,1 Source: K. Debackere et al., in prep.
Balancing science & Tech Transfer
Conclusion: High quality basic science & tech transfer are compatible